In sum, these data not only suggest that tumorally expressed IGFBP5 may serve as a useful marker to assess responsiveness of cancer cells to IGF1R inhibitors, but also that IGFBP5 is causatively involved in the acquisition of resistance to these drugs. This evidence concerns the gene IGF1R and cancer.